Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of MAQ-001 in Advanced Solid Tumors
NCT06514651Phase 1Recruiting
- Sponsor
- MabQuest Therapeutics
- Start
- Jun 2024
- Primary completion
- Jun 2026
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label trial of MAQ-001 in solid tumor (advanced stage) and lymphoma (5 arms), sponsored by MabQuest Therapeutics. Primary endpoints: Maximum Tolerated Dose up to 2 years, Maximum Administered Dose up to 2 years and 3 more. Started Jun 2024; status: recruiting.
02
Drugs
MAQ-001
03
Conditions
solid tumor (advanced stage)lymphoma
Beyond the preview
Go deeper on NCT06514651.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06514651.